The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle

被引:12
作者
Ruddock, MW [1 ]
Burns, DM [1 ]
Murphy, LE [1 ]
O'Rourke, MG [1 ]
Hirst, DG [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, Radiat Sci Grp, Newtonabbey BT37 0QB, Antrim, North Ireland
关键词
nicotinamide; emesis; tumours; radiosensitizer;
D O I
10.1016/S0167-8140(00)00194-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Nicotinamide (NA) is currently undergoing clinical trials as a tumour radiosensitizer. The dose that can be administered is currently 80 mg/kg per day, but this may be restricted to 60 mg/kg per day by the high incidence of nausea and vomiting. To investigate some of NA's underlying mechanisms of action, we have used an ex vivo system to study the direct effect of this drug, over a wide range of concentrations, on isolated spontaneously active rat ileum. Effects on the gut were compared with the action of NA on skeletal and vascular smooth muscle. Materials and methods: Isolated rat ileum rings were perfused with oxygenated Krebs' solution in an organ bath. NA (1 mu M to 10 mM) was introduced to the perfusate and the change in amplitude of spontaneous peristaltic activity recorded. Dissected frog sartorius muscle was bathed in modified oxygenated Ringer's solution in an organ bath. The muscle was electrically stimulated to generate isometric contractions. Tension was then measured before and after the addition of a range of NA concentrations (8.2-24.6 mM) to the organ bath. Results: NA inhibited peristalsis in the ileum in a dose-dependent manner. At a drug concentration of 1 mM the amplitude of contractions was reduced to <50% of the initial control value. NA had no effect on the electrically induced contractions in the isolated frog sartorius muscle. Conclusions: Gut smooth muscle is highly sensitive to the relaxant effect of NA producing 50% relaxation at a concentration similar to 10 fold lower than that required in rat arterial smooth muscle, while having no effect on non-mammalian skeletal smooth muscle. This may provide explanations for the occurrence of emesis in patients undergoing combined nicotinamide therapies and highlight possible alternatives available to counter this unwanted side-effect. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:253 / 257
页数:5
相关论文
共 34 条
[1]   CHEMICAL ENERGY USAGE AND MYOSIN LIGHT CHAIN PHOSPHORYLATION IN MAMMALIAN SKELETAL-MUSCLE [J].
BARSOTTI, RJ ;
BUTLER, TM .
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 1984, 5 (01) :45-64
[2]   Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy:: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer [J].
Bernier, J ;
Stratford, MRL ;
Denekamp, J ;
Dennis, MF ;
Bieri, S ;
Hagen, F ;
Kocagöncü, O ;
Bolla, M ;
Rojas, A .
RADIOTHERAPY AND ONCOLOGY, 1998, 48 (02) :123-133
[3]   ACTIVATION OF SKELETAL-MUSCLE MYOSIN LIGHT CHAIN KINASE BY CALCIUM(2+) AND CALMODULIN [J].
BLUMENTHAL, DK ;
STULL, JT .
BIOCHEMISTRY, 1980, 19 (24) :5608-5614
[4]   INTERACTIONS BETWEEN PRIMIDONE, CARBAMAZEPINE, AND NICOTINAMIDE [J].
BOURGEOIS, BFD ;
DODSON, WE ;
FERRENDELLI, JA .
NEUROLOGY, 1982, 32 (10) :1122-1126
[5]   PHARMACOKINETICS AND TOLERANCE OF NICOTINAMIDE COMBINED WITH RADIATION-THERAPY IN PATIENTS WITH GLIOBLASTOMA-MULTIFORME [J].
CARTEI, F ;
DANESI, R ;
DUCCI, F ;
FATIGANTE, L ;
CACIAGLI, PG ;
DELTACCA, M ;
LADDAGA, M .
ACTA ONCOLOGICA, 1994, 33 (08) :969-973
[6]  
CHOUINARD G, 1977, LANCET, V1, P249
[7]   NICOTINAMIDE PHARMACOKINETICS IN PATIENTS [J].
DRAGOVIC, J ;
KIM, SH ;
BROWN, SL ;
KIM, JH .
RADIOTHERAPY AND ONCOLOGY, 1995, 36 (03) :225-228
[8]  
ELLIOTT RB, 1993, ANN NY ACAD SCI, V696, P333
[9]  
GREEN RG, 1970, SCHIZOPHRENIA, V2, P70
[10]  
HAWKINS DR, 1968, J SCHIZOPHR, V2, P3